Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853635 | 0.93 | BCL2 (0.72) | BCL2 | |
| SCHEMBL21668731 | 0.90 | BCL2 (0.56) | BCL2 | |
| SCHEMBL19854194 | 0.88 | BCL2 (0.69) | BCL2 | |
| SCHEMBL19853741 | 0.87 | BCL2 (0.82) | BCL2 | |
| SCHEMBL19853639 | 0.86 | BCL2 (0.70) | BCL2 | |
| SCHEMBL19853634 | 0.86 | BCL2 (0.80) | BCL2 | |
| SCHEMBL21573184 | 0.86 | BCL2 (0.75) | BCL2 | |
| SCHEMBL19853739 | 0.86 | BCL2 (0.76) | BCL2 | |
| SCHEMBL24520027 | 0.85 | BCL2 (0.69) | BCL2 | |
| SCHEMBL22562885 | 0.85 | BCL2 (0.74) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020024916-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR OR BCL-2/BCL-XL DUAL INHIBITOR AND BTK INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020024834-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020024820-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020024826-A1 | SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-02-06 | — | — | WO | disclosed |